[{"data":1,"prerenderedAt":126},["ShallowReactive",2],{"drug-digoxin-immune-fab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":54,"warnings":55,"renal":56,"monitoring":57,"interactions":58,"review":59,"examples":62,"atc":63,"iran":65,"links":72,"populations":87,"usApproval":121},"digoxin-immune-fab",1,{"fa":7,"en":8},"آنتی‌بادی ضد دیگوکسین (DigiFab)","Digoxin immune fab (DigiFab)","various",{"fa":11,"en":12},"پادزهر دیگوکسین","Digoxin antidote",[14],{"name":15,"market":16},"DigiFab","US",[18,19,20,11],"digifab","دیجی فب","digibind",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"vial-40","powder-for-injection","iv","40 mg vial (binds about 0.5 mg digoxin)",{"amount":28,"unit":29,"perUnit":30},40,"mg","vial",[16],[33],{"source":34,"section":35},"fda-digifab","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":44,"unit":29,"dose":45,"refs":49},"std","digoxin-toxicity",{"fa":41,"en":42},"مسمومیت با دیگوکسین — تعداد ویال بر اساس مقدار مصرف یا سطح سرمی","Digoxin toxicity — vials by amount ingested or serum level",{},"notCalculated",{"reason":46},{"fa":47,"en":48},"برچسب: مصرف حاد با مقدار نامعلوم و بدون سطح: ۲۰ ویال (در کودک زیر ۲۰ kg مراقب حجم؛ ۱۰ ویال و سپس ۱۰ ویال دیگر در صورت نیاز). مسمومیت مزمن بدون سطح: بزرگسال و کودک ۲۰ kg به بالا ۶ ویال؛ زیر ۲۰ kg یک ویال. مقدار مصرف معلوم: ویال = مقدار دیگوکسین (mg) ÷ ۰٫۵. سطح معلوم: ویال = (سطح دیگوکسین ng\u002FmL × وزن kg) ÷ ۱۰۰. انفوزیون حداقل ۳۰ دقیقه.","Label: acute ingestion, unknown amount, no level: 20 vials (watch volume in children \u003C20 kg; 10 vials then 10 more if needed). Chronic toxicity, no level: adults and children ≥20 kg 6 vials; \u003C20 kg 1 vial. Known amount: vials = digoxin ingested (mg) ÷ 0.5. Known level: vials = (serum digoxin ng\u002FmL × weight kg) ÷ 100. Infuse over at least 30 min.",[50,52],{"source":34,"section":51},"2.1",{"source":34,"section":53},"2.2",[],[],[],[],[],{"status":60,"reviewer":61,"date":61},"unverified",null,[],[64],"V03AB24",{"status":66,"refs":67},"not-found",[68],{"source":69,"section":70,"url":71},"darooyab-generic","G-1949\u002FDigoxin-specific-Antibody-Fragments","https:\u002F\u002Fwww.darooyab.ir\u002FG-1949\u002FDigoxin-specific-Antibody-Fragments",[73,77,81,84],{"kind":74,"url":75,"label":76},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=103910","BLA103910",{"kind":78,"url":79,"label":80},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=c05ee6a5-c98b-45f4-83fd-40781639d653","FDA DigiFab",{"kind":82,"url":83,"label":64},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=V03AB24",{"kind":85,"url":71,"label":86},"darooyab","Digoxin-specific-Antibody-Fragments",{"pregnancy":88,"lactation":97,"pediatric":105,"geriatric":113},{"level":89,"text":90,"quote":93,"refs":94},"caution",{"fa":91,"en":92},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Animal reproduction studies have not been conducted with DIGIFAB.",[95],{"source":34,"section":96},"8.1",{"level":89,"text":98,"quote":101,"refs":102},{"fa":99,"en":100},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk, caution should be exercised when DIGIFAB is administered to a nursing woman.",[103],{"source":34,"section":104},"8.2",{"level":89,"text":106,"quote":109,"refs":110},{"fa":107,"en":108},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety data in pediatric population is limited.",[111],{"source":34,"section":112},"8.4",{"level":89,"text":114,"quote":117,"refs":118},{"fa":115,"en":116},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","There is no evidence that the efficacy of DIGIFAB would be altered due to advanced age alone; however, elderly patients have a higher chance of having impaired renal function and therefore should be monitored more closely for recurrent toxicity (See 5.3 Use of DIGIFAB in renal failure).",[119],{"source":34,"section":120},"8.5",{"kind":122,"refs":123,"id":76},"BLA",[124],{"source":34,"section":125},"SPL approval \u002F marketing category",1792108420586]